Chiesi Farmaceutici SpA - Company Profile
Powered by 
All the data and insights you need on Chiesi Farmaceutici SpA in one report.
$295
- Save hours of research time and resources with
our up-to-date Chiesi Farmaceutici SpA Strategy Report
- Understand Chiesi Farmaceutici SpA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View up-to-date information on Chiesi Farmaceutici SpA’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 02 May 2022 | Chiesi Farma Receives Rights to Portfolio of Therapeutic Monoclonal Antibodies from Allinaire Therapeutics | Licensing Agreement |
Chiesi Farmaceutici SpA
|
Allinaire Therapeutics LLC
|
| 30 Nov 2021 | Chiesi Farmaceutici Enters into Licensing Agreement with UCB | Licensing Agreement |
Chiesi Farmaceutici SpA
|
UCB SA |
| 25 May 2021 | Chiesi Farmaceutici SpA Enters Phase III Clinical Trial Agreement with CRU Hungary Ltd for (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) (GDCT0419351) | Contract Service Agreement |
Chiesi Farmaceutici SpA
|
CRU Hungary Ltd
|
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer